PEOPLE ON THE MOVE
CluePoints
CluePoints, a provider of risk-based monitoring (RBM) for clinical trials, has appointed three directors.
John Colby and Elizabeth Polvent will join the company’s US business development team as Senior Directors on the East and West coasts, respectively.
Jean Stéphenne, President of the Board of Directors at GSK Biologicals, will become a member of CluePoint’s board.
In an exclusive interview this month, Parexel’s CEO told us risk-based monitoring, a system for calculating when visits should be made to clinical trials, is possible thanks to sponsors increasingly sharing more data with CROs.
